bioAffinity Technologies, Inc. Receives Nasdaq Delisting Notice: What Investors Need to Know
Key Points from the Report
- Nasdaq Delisting Notice Received: bioAffinity Technologies, Inc. (the “Company”) has received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC, notifying the Company that it is not in compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.
- Trigger for Non-Compliance: The Company’s listed securities have closed at less than \$1.00 per share over the previous thirty consecutive business days, from June 16, 2026 through July 29, 2026, violating Nasdaq Listing Rule 5550(a)(2).
- Potential Consequences: Failure to meet the Nasdaq listing requirement could lead to the Company’s common stock and warrants being delisted from The Nasdaq Capital Market, which may significantly impact share liquidity and value.
- Emerging Growth Company: bioAffinity Technologies, Inc. is classified as an emerging growth company, which may influence its regulatory and reporting obligations.
- Forward-Looking Statements: The report contains forward-looking statements regarding the timing of the hearing before Nasdaq and the outcome of any appeal, warning that decisions and timelines may be shorter than typical and potentially unfavorable for the Company.
Details Shareholders Must Know
This development is highly significant and potentially price-sensitive for shareholders.
The receipt of a Nasdaq delisting notice often triggers investor concern, as it signals the risk of the Company’s securities being removed from a major trading platform. Such an event could:
- Limit the Company’s ability to attract new investors due to reduced market visibility and liquidity.
- Potentially lead to increased volatility or a decline in share price as existing holders react to the news.
- Force the Company to take remedial actions, such as a reverse stock split, to regain compliance—actions which may further impact shareholder value.
Current Status and Next Steps
The Company has been notified that its closing bid price has been below \$1.00 for 30 consecutive business days, triggering non-compliance with Nasdaq’s minimum bid price requirement.
The Company now faces a timeline to address this deficiency. While the report does not specify the exact process or deadlines, typically, Nasdaq provides a compliance period (often 180 calendar days) to regain compliance, after which the Company may appeal or request a hearing.
The outcome of such hearings or appeals is uncertain, and the panel’s decision timeline may be shorter than expected, according to the Company’s own forward-looking statements.
Securities Affected
- Common Stock: Traded under the symbol BIAF on The Nasdaq Capital Market, with a par value of \$0.007 per share.
- Warrants to Purchase Common Stock: Traded under the symbol BIAFW on The Nasdaq Capital Market.
Other Disclosures
- The Company has not filed any written communications, soliciting material, or made pre-commencement tender offers in relation to this event.
- The Company has not elected to use the extended transition period for complying with any new or revised financial accounting standards.
- There is no indication of a change in the Company’s name or address.
What This Means for Investors
Investors should be aware that receipt of a Nasdaq delisting notice is a material event that could significantly affect the value and liquidity of bioAffinity Technologies, Inc. shares and related warrants.
The risk of delisting may lead to increased volatility and potential downward pressure on the share price. The Company’s ability to regain compliance, the timing of any Nasdaq actions, and the outcome of hearings or appeals remain uncertain.
Shareholders are advised to monitor further disclosures from the Company and Nasdaq closely, as any updates on compliance or delisting status could further impact the stock price.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with their financial advisors before making investment decisions. The information is based on a Form 8-K filing by bioAffinity Technologies, Inc. dated July 30-31, 2026. Actual outcomes may differ from forward-looking statements contained herein. The publisher assumes no obligation to update this article for subsequent developments.
